This inventor holds 2 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents. Top assignees: National Cancer Center, Eisai R&d Management Co., Ltd., Infocom Corporation. Active years: 2019-2025.
Company Filing History:
2 out of 263 
1 out of 530 
1 out of 2 Years Active: 2019-2025
Title: Tatsuhiro Shibata: Innovator in Cancer Therapeutics
Introduction
Tatsuhiro Shibata is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of cancer therapeutics, particularly in the development of innovative treatment agents. With a total of 2 patents, his work focuses on addressing critical challenges in cancer treatment.
Latest Patents
Shibata's latest patents include a therapeutic agent for bile duct cancer. This invention comprises 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof. Additionally, he has developed a patent related to the oncogene NRF2. This invention provides a marker that can be used as an indicator for efficacy prediction of an mTOR-related anticancer agent or for prognostic prediction. It also includes a method for efficacy evaluation of a cancer drug by detecting NRF2 abnormality, along with a novel anticancer agent targeting NRF2.
Career Highlights
Throughout his career, Tatsuhiro Shibata has worked with esteemed organizations such as the National Cancer Center and Infocom Corporation. His experience in these institutions has allowed him to contribute significantly to cancer research and therapeutic development.
Collaborations
Shibata has collaborated with notable colleagues, including Shigeru Saito and Yasuhito Arai. These partnerships have further enhanced his research and innovation in the field of cancer therapeutics.
Conclusion
Tatsuhiro Shibata is a dedicated inventor whose work in cancer therapeutics has the potential to make a significant impact on treatment options for patients. His innovative patents and collaborations reflect his commitment to advancing medical science.